Notice Number: NOT-CA-19-015

Key Dates
Release Date: December 19, 2018

Issued by
National Cancer Institute (NCI)

Purpose

The purpose of this Notice is to inform potential applicants that the National Cancer Institute (NCI) is participating, effective immediately, in PAR-19-064, Mechanism for Time-Sensitive Drug Abuse Research (R21 Clinical Trial Optional).

The following changes have been made in PAR-19-064 under each of the headings (below) to reflect NCI's participation in this funding opportunity announcement (FOA):

Part 1. Overview Information

Components of Participating Organizations

National Cancer Institute (NCI)

Catalog of Federal Domestic Assistance (CFDA) Number(s)

93.399

Part 2. Section I. Funding Opportunity Description

[The text in the paragraph below is hereby inserted in this section at the end of the subsection entitled "Purpose" and just before the start of the subsection entitled "Special Considerations" so that the research topics of particular relevance and programmatic interest to the NCI in the context of this FOA are summarily presented to all interested parties.]

"In addition to research areas already listed in this Section, the National Cancer Institute (NCI) is interested in applications describing research projects that will address an extraordinary opportunity in this area by utilizing natural experiment, observational, or ecological designs to study the population impact(s) of the court-ordered, tobacco-related corrective statements implemented as part of the Department of Justice's racketeering case, "United States v. Philip Morris USA, Inc.," on television and in newspapers, on tobacco company Web sites and cigarette pack onserts, and possibly at point-of-sale."

Part 2. Section VII. Agency Contacts

Scientific/Research Contact(s)

Kelly D. Blake, Sc.D.
National Cancer Institute
Telephone: 240-281-5934
Email: kelly.blake@nih.gov

Financial/Grants Management Contact(s)

Crystal Wolfrey
National Cancer Institute
Telephone: 240-276-6277
Email: wolfreyc@mail.nih.gov

All other aspects of this FOA remain unchanged.

Inquiries

Please direct all inquiries to:

Kelly D. Blake, Sc.D.
National Cancer Institute
Telephone: 240-281-5934
Email: kelly.blake@nih.gov